Alphadent NV

Product FSN: 694 AR



1

Rev 1: September 2018 FSN Ref: 2020-06-22_D200608

FSCA Ref: 2020-06-22_D200608

Date: 22.06.2020

Urgent Field Safety Notice Device Commercial Name

For Attention of*:

Customers and wholesale distributions Notified Bodies Competent national authorities

Contact details of local representative (name, e-mail, telephone, address etc.)*
Beckers d.o.o.: vesna@beckers.si, ceka.rbeckers@gmail.com 24 SPODNJI TRG
4220 SKOFJA LOKA SLOVENIË, Tel: +386 51415280
Henry Schein Services: info@henryschein.de, Kerstin.Klotz@henryschein.de Monzastraße 2A
63225 LANGEN DUITSLAND, tel: +49 6103-757-7111
SSP Politool: ssp.aalen@t-online.de, ceka-preciline@ssp-schulz.de, Adress: Schellingstraße
27, 73431 AALEN DUITSLAND, tel: +49 (0) 7361 – 9 38 7 17
CEKA-Ankervertrieb Deutschland: <u>bielicki@ceka-vertrieb.de</u> , Adress: AKAZIENSTRASSE 7 A
30169 HANNOVER DUITSLAND, tel: +49 (0) 511 – 8070041
Arseus Lab BV: janpieter.reitsma@arseus-lab.nl Adress: Veluwezoom 16 ,1327 AG
ALMERE NEDERLAND, tel: +31 36 521 83 32
Dental Union BV: tonbosma@dentalunion.nl, adrianajongen@dentalunion.nl, Adress:
Ravenswade 54K, 3439 LD NIEUWEGEIN NEDERLAND, tel: +31 (0)30-2815565
DK DENTALDEPOT A/S: mb@dkdentaldepot.dk , tel : +45 3614 0005
Plantech Dental: michaela.koenig@plantech-dental.at, Adress: Endresstraße 19/11
1230 WIEN OOSTENRIJK, tel: 01/865 65 92-0

FSN Ref: 2020-06-22_D200608

Rev 1: September 2018 FSCA Ref: 2020-06-22_D200608

Urgent Field Safety Notice (FSN) Device Commercial Name Risk addressed by FSN

		1. Information on Affected Devices*	
1	1. Device Type(s)*		
+	Retention part of dental attachments. Non sterile device.		
	694 AR (Defective piece)	
	694 AR OL 0285 TI OL 0285 IR OL 694 R OL 694 RPR OL 724 RPR OL 0885 TI		
1	2. Commercial r	ame(s)	
	Add as Appendix if nec		
	694 AR	CEKA M3 RETENTION PART SPACER 2+2 PCS	
	OL 0285 TI	REVAX M3 TI/SPACER	
	OL 0285 IR	REVAX M3 IR/SPACER	
	OL 694 R	CEKA M3 IR/SPACER	
	OL 694 RPR	CEKA M3 PR/SPACER	
	OL 724 RPR	CEKA M3 PR/SPACER	
	OL 0885 TI	REVAX M3 AXIAL TI/SPACER	
1	3 Unique Devic	e Identifier(s) (UDI-DI)	
	Not Applicable		
1	4. Primary clinic	al purpose of device(s)*	
	How the device(s) is/are used in the clinical setting/intended use.		
	CEKA and Preci-Li	ne retention parts and base rings	
		e used as a retention part to thread in males (spring pin). They form	
	part of an attachment system and are incorporated into a dental prosthesis or a post coping by the dental technician or dentist.		
	Long-term in-oral		

1	Device Model/Catalogue/part number(s)*
	694 AR
	OL 0285 TI
	OL 0285 IR
	OL 694 R
	OL 694 RPR
	OL 724 RPR
	OL 0885 TI
1	6. Software version
	Not Applicable
1	7. Affected serial or lot number range
	Lot D200608
1	8. Associated devices
	None

				
	2 Reason for Field Safety Corrective Action (FSCA)*			
2	1. Description of the product problem*			
	The spring pin 694 C is not screwing till the end in the retention part 694 AR , defect of			
	retention part 694 AR thread.			
•				
2	2. Hazard giving rise to the FSCA*			
-	Details of the greatest hazard to the patient/end user that the advice/action is intended to			
· ·	mitigate. Make clear whether risk is to user, patient or both. Should also try to indicate the			
	residual risk if the FSN advice/action is taken.			
	Lower device lifetime for the patient			
2	3. Probability of problem arising			
	Moderate probability			
·	······································			
2	4. Predicted risk to patient/users			
	Prothesis/device could break or split; swallowing broken components; open wound within			
	patients mouth (product of severity 3 x probability 3) resulting in RPN 9 which is moderate			
	risk managed to an acceptable level according to the product's risk assessment			
2	5. Further information to help characterise the problem			
	Only one complaint/incidence occurred from one customer for a defect that can be easily			
	seen when screwing the components together by the user. The manufacturer's initial			
	investigation advises the problem relates only to this lot of product. No injury reported for this incident.			
. 2	6. Background on Issue			
2	One customer complaint received: The spring pin 694 C is not screwing till the end in the			
	retention part 694 AR. The manufacturer's initial investigation advised that cause of the			
	defect was related to cutting tool used in the production for the concerned lot. Further			
	investigations are undergoing to confirm the root cause. The Manufacturer advised no other			
	products are affected.			
	An additional control measure is put in place for better quality control. The Manufacturer is			
	finalising investigation and corrective actions necessary. No other products are being			
	produced until the investigation and corrective actions have been completed.			
2	7. Other information relevant to FSCA			
2	Not applicable			
·				
L				

	3. Type of Action to mitigate the risk*				
3.	1.	Action To Be Taken by			
		Identify Device Quarantin		Return evice	□ Destroy Device
		□ On-site device modification	/inspection		
		Follow patient managemer	t recommendations		
		□ Take note of amendment/r	einforcement of Instructio	ons For Us	e (IFU)
		Other None			
		Provide further details of the a	action(s) identified.		
3.	2.	2. By when should the Specify where critical to patient/end user safety			
		action be completed?			
		10.07.2020			
3.	3.	3. Particular considerations for: Choose an item.			
		Is follow-up of patients or re	eview of patients' previ	ous resul	ts recommended?
		Choose an item.			
		Follow up is required			
		The defect should be easily i		-	
		recommended not to remove			ection risk. Informing the
		patient is up to the discretio	n of the dental practitic	oner.	
3.	4.	Is customer Reply Require	d? * YES		Choose an item.
		yes, form attached specifyin			10.07.2020
3.	5.	Action Being Taken by	the Manufacturer		
		_			
] On-site device modifica	•	ction
			IFU or labelling change		
		□ Other □] None		
		Provide further details of the action(s) identified.			
3	6.	By when should the	Specify where critic	al to patie	nt/end user safety
		action be completed?	10.07.2020		
3.	7.	7. Is the FSN required to be communicated to the patient Choose an item.			
		/lay user?			No
3	8.				
3	8.	If yes, has manufacturer pr user in a patient/lay or non-			
		Choose an item. Choose	an item. NOT Appli	cable	

		General Information*		
4.	1. FSN Type*	Choose an item.		
		Voluntary FSN		
4.	2. For updated FSN, reference	Provide reference and date of previous FSN if		
	number and date of previous	relevant		
	FSN	Not applicable		
4.	3. For Updated FSN, key new inform	ation as follows:		
		ices affected and/or action to be taken.		
	Not Applicable			
4.	4. Further advice or information	Choose an item.		
	already expected in follow-up FSN? *	Follow up will be provided by 31.07.2020		
	5. If follow-up FSN expected, what is	the further advice expected to relate to:		
4	Eg patient management, device modi	fications etc		
	Follow up to update on FSN completion			
	6. Anticipated timescale for follow-	For provision of updated advice.		
4	up FSN	31.07.2020		
4.	7. Manufacturer information			
	(For contact details of local representative			
	a. Company Name	Only necessary if not evident on letter-head.		
	b. Address	Only necessary if not evident on letter-head.		
	c. Website address	Only necessary if not evident on letter-head.		
4.		ority of your country has been informed about		
	this communication to customers.	* yes		
4.	9. List of attachments/appendices:	None		
4.	10. Name/Signature	Insert Name and Title here and signature below		
	AD	Abbas EL DIKA		
		Quality and Regulatory Manager		

Transmission of this Field Safety Notice
This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)
Please transfer this notice to other organisations on which this action has an impact. (As appropriate)
Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.
Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback*

Note: Fields indicated by * are considered necessary for all FSNs. Others are optional. $_3$